Heart Valve Matters

Michael Mack and Carole Warnes discuss the challenges of continued treatment for adults with congenital heart disease and the importance of lifelong care.

Continuing the conversation, Juan Granada hears about Guido Ascione’s recent presentation on the global burden of degenerative mitral valve disease at NY Valves 2025.

Juan Granada speaks with Greg Roth about how the GBD data set is used to assess global trends and determine what health problems need to be addressed by the medical community worldwide.

Michael Mack and Caroline Berchuck discuss how the expectations of healthcare delivery in the United States are shifting due to expanded capabilities of AI and digital technology.

Juan Granada and Pierre Elias continue their conversation on artificial intelligence, including the practical ways it can be implemented in the detection of structural heart disease.

Isaac George discusses the one-year clinical results of the novel polymeric leaflet TRIA valve for patients undergoing surgical mitral valve replacement.

Suzanne Baron and David Elison discuss when to intervene in cases of asymptomatic aortic stenosis based on the complete patient profile. 

Brian Lindman, Rahul Sharma, and Sreek Vemulapalli share the benefits of using artificial intelligence tools to assist in identifying patients with aortic stenosis.

Brian Lindman, Sammy Elmariah, and David Wood explain how echocardiogram alerts are assisting in the management and evaluation of aortic stenosis patients.

Bernard Prendergast and Jordan Strom discuss the evolution of AS referral and how earlier treatment impacts patient outcomes. 

Philippe Généreux, Brad Oldemeyer, and Jennifer Daniel share their experiences treating asymptomatic aortic stenosis patients in the EARLY TAVR trial.

Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management.

Bernard Prendergast and Philippe Généreux detail the EARLY TAVR trial design and outcomes.

Juan Granada and Pierre Elias discuss how AI is an essential tool for improving screening access and increasing early diagnosis of valvular heart disease.

Juan Granada and Brian Lindman share insights on tools and data that can be used to achieve earlier diagnosis and intervention in valvular heart disease.

Sammy Elmariah and David Playford discuss the ways technology and AI can be used to assist in better treatment and diagnosis of severe aortic stenosis. 

Martha Gulati and Kathyn Berlacher talk about tangible ways to improve women's cardiovascular care, including nontraditional, patient-centered solutions.

Clyde Yancy, Suzanne Baron, and Bruce Rutkin discuss ways to address the undertreatment of CVD in women at the patient, provider, structural, and societal levels.

Clyde Yancy talks to Sharonne Hayes and Robert Harrington about the barriers that have historically hindered diagnosing heart disease in women, including sex differences in disease presentation and outdated biases.

Clyde Yancy talks to Priya Freaney and Nisha Parikh about the landscape of cardiovascular care for women and how it can be improved, both for patients and women training to be cardiologists.

Clyde Yancy, Roxana Mehran, and Howard Herrmann discuss strategies for increasing clinical trial enrollment among women, including targeting disease phenotypes and sex-specific trials.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

Sreekanth Vemulapalli asks Ryan Ahern about potential data sources that can be used to sustain long-term follow-up in pivotal trials.

Vinod Thourani and Larry Epstein explore the current field of tricuspid intervention as well as challenges within lead management with additional commentary from Ami Bhatt.

Paul Sorajja and Vinod Thourani discuss the key considerations for choosing between transcatheter tricuspid repair and replacement.